Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux

This article was originally published in The Pink Sheet Daily

Executive Summary

Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.

You may also be interested in...

UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux

Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.

Bristol To Name New R&D Head Shortly

Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.

Chiron Fluvirin Remediation Plan Design Underway

The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts